Overview

Efficacy of Polatuzumab, Bendamustine and Rituximab in Patients With Relapsed/ Refractory Mantle Cell Lymphoma

Status:
Not yet recruiting
Trial end date:
2027-05-24
Target enrollment:
Participant gender:
Summary
Polatuzumab, bendamustine and rituximab in patients with relapsed/ refractory mantle cell lymphoma
Phase:
Phase 2
Details
Lead Sponsor:
Medical University of Vienna
Treatments:
Bendamustine Hydrochloride
Rituximab